The finding that GH replacement therapy induced a small reduction of hepatic fat content in NAFLD patients with GHD [147] offers the reasonable hope to resolve this ongoing scientific controversy by addressing this topic from a therapeutic perspective thanks to adequately sized future large therapeutic trials. The gene discussed is GH1; the disease is metabolic dysfunction-associated steatotic liver disease.